Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12104/45792
Title: Masitinib for the treatment of mild to moderate Alzheimer's disease
Author: Folch J
Petrov D
Ettcheto M
Pedros I
Abad S
Beas-Zárate, Carlos
Lazarowski A
Marin M
Olloquequi J
Auladell C
Camins A.
Issue Date: 2015
Abstract: Alzheimer's disease (AD) is a degenerative neurological disorder that is the most common cause of dementia and disability in older patients. Available treatments are symptomatic in nature and are only sufficient to improve the quality of life of AD patients temporarily. A potential strategy, currently under investigation, is to target cell-signaling pathways associated with neurodegeneration, in order to decrease neuroinflammation, excitotoxicity, and to improve cognitive functions. Current review centers on the role of neuroinflammation and the specific contribution of mast cells to AD pathophysiology. The authors look at masitinib therapy and the evidence presented through preclinical and clinical trials. Dual actions of masitinib as an inhibitor of mast cell-glia axis and a Fyn kinase blocker are discussed in the context of AD pathology. Masitinib is in Phase III clinical trials for the treatment of malignant melanoma, mastocytosis, multiple myeloma, gastrointestinal cancer and pancreatic cancer. It is also in Phase II/III clinical trials for the treatment of multiple sclerosis, rheumatoid arthritis and AD. Additional research is warranted to better investigate the potential effects of masitinib in combination with other drugs employed in AD treatment. © 2014 Informa UK, Ltd.
URI: http://www.scopus.com/inward/record.url?eid=2-s2.0-84930465723&partnerID=40&md5=fab4c5c69bb40f7fd9a949422a2d5466
http://hdl.handle.net/20.500.12104/45792
Appears in Collections:Producción científica UdeG

Files in This Item:
There are no files associated with this item.


Items in RIUdeG are protected by copyright, with all rights reserved, unless otherwise indicated.